Completed
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
I8F-MC-GPGK - ClinicalTrials.gov - NCT03954834
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
How long will I be in the trial?
The study will last approximately 47 weeks and may include about 15 visits.
Completed
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
I8F-MC-GPGK - ClinicalTrials.gov - NCT03954834
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
How long will I be in the trial?
The study will last approximately 47 weeks and may include about 15 visits.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have type 2 diabetes
Participant must be naïve to diabetes injectable therapies and have not used any oral antihyperglycemic medications (OAM) during the 2 months preceding screening
Participant must have hemoglobin A1c ≥7.0% and ≤9.5%
Participant must be of stable weight
Participant must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must NOT
Participant must not have type 1 diabetes
Participant must not have pancreatitis
Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participant must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
472
Trial Dates
June 2019 - October 2020
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have type 2 diabetes
Participant must be naïve to diabetes injectable therapies and have not used any oral antihyperglycemic medications (OAM) during the 2 months preceding screening
Participant must have hemoglobin A1c ≥7.0% and ≤9.5%
Participant must be of stable weight
Participant must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must NOT
Participant must not have type 1 diabetes
Participant must not have pancreatitis
Participant must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participant must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide, Placebo
Could I receive a Placebo?
yes
Enrollment Goal
472
Trial Dates
June 2019 - October 2020
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Adult Type 2 Diabetes Resources
